What Do We Know about Medication Adherence Interventions in Inflammatory Bowel Disease, Multiple Sclerosis and Rheumatoid Arthritis? A Scoping Review of Randomised Controlled Trials

Kathryn King,1 Serena McGuinness,1 Natalie Watson,1 Christine Norton,1 Trudie Chalder,2 Wladyslawa Czuber-Dochan1 1Florence Nightingale Faculty Nursing, Midwifery and Palliative Care, King’s College London, London, UK; 2Department of Psychological Medicine, Institute of Psychiatry, Psychology and Ne...

Full description

Bibliographic Details
Main Authors: King K, McGuinness S, Watson N, Norton C, Chalder T, Czuber-Dochan W
Format: Article
Language:English
Published: Dove Medical Press 2023-12-01
Series:Patient Preference and Adherence
Subjects:
Online Access:https://www.dovepress.com/what-do-we-know-about-medication-adherence-interventions-in-inflammato-peer-reviewed-fulltext-article-PPA
_version_ 1797391169428127744
author King K
McGuinness S
Watson N
Norton C
Chalder T
Czuber-Dochan W
author_facet King K
McGuinness S
Watson N
Norton C
Chalder T
Czuber-Dochan W
author_sort King K
collection DOAJ
description Kathryn King,1 Serena McGuinness,1 Natalie Watson,1 Christine Norton,1 Trudie Chalder,2 Wladyslawa Czuber-Dochan1 1Florence Nightingale Faculty Nursing, Midwifery and Palliative Care, King’s College London, London, UK; 2Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UKCorrespondence: Kathryn King, Email Kathryn.king@kcl.ac.ukPurpose: Between 53% and 75% of people with inflammatory bowel disease, 30%– 80% with rheumatoid arthritis, and up to 50% with multiple sclerosis do not take medications as prescribed to maintain remission. This scoping review aimed to identify effective adherence interventions for inflammatory bowel disease, but with few studies found, multiple sclerosis and rheumatoid arthritis were included to learn lessons from other conditions.Methods: Full and pilot randomised controlled trials testing medication adherence interventions for inflammatory bowel disease, multiple sclerosis, and rheumatoid arthritis conducted between 2012 and 2021 were identified in six electronic databases.Results: A total of 3024 participants were included from 24 randomised controlled trials: 10 pilot and 14 full studies. Eight investigated inflammatory bowel disease, 12 rheumatoid arthritis, and four multiple sclerosis. Nine studies (37.5%) reported significantly improved medication adherence, all involving tailored, personalised education, advice or counselling by trained health professionals, with five delivered face-to-face and 1:1. Quality of effective interventions was mixed: five rated high quality, two medium and two low quality. Interventions predominantly using technology were likely to be most effective. Secondary tools, such as diaries, calendars and advice sheets, were also efficient in increasing adherence. Only 10 interventions were based on an adherence theory, of which four significantly improved adherence.Conclusion: Tailored, face-to-face, 1:1 interactions with healthcare professionals were successful at providing personalised adherence support. Accessible, user-friendly technology-based tools supported by calendars and reminders effectively enhanced adherence. Key components of effective interventions should be evaluated and integrated further into clinical practice if viable, whilst being tailored to inflammatory conditions.Plain Language Summary: Introduction: Inflammatory bowel disease (IBD), multiple sclerosis (MS), and rheumatoid arthritis (RA) are inflammatory diseases where the immune system causes inflammation by mistakenly attacking itself. These lifelong conditions cannot be cured, but can usually be controlled by medication. Medication is most effective when taken as prescribed, called “adherence”. For multiple reasons, between five and eight in 10 people with IBD, RA, and MS do not take medications as advised. This review aimed to identify research that tested ways to help people living with IBD, MS, and RA take medications as prescribed. Identifying and understanding what helps can increase patient well-being and improve quality of life through better controlled inflammatory conditions.Methods: Studies testing medication adherence interventions for IBD, MS, and RA conducted between 2012 and 2021 were identified from six electronic databases.Results: A total of 3024 people with inflammatory conditions took part in 24 studies (eight on IBD, four on MS, and 12 on RA). Nine studies reported significantly improved medication adherence, all involving personalised education, advice or counselling by trained health professionals, with five delivered face-to-face and individually. Interventions predominantly using technology were the most effective. Diaries, calendars, and advice sheets also increased adherence. Ten of the interventions were based on an adherence theory, of which four improved adherence.Conclusions: Personalised adherence support was successful when:tailored to patient,one-to-one and face-to-face,with healthcare professionals,involving technology-based tools, andsupported by calendars/reminders.Components of effective interventions should be used in clinical practice where possible, made specific to each inflammatory condition.Keywords: IBD, MS, RA, treatment, medicine, drug, concordance
first_indexed 2024-03-08T23:27:57Z
format Article
id doaj.art-b4cfd91af1ca4e2c82449d1aa7337fb6
institution Directory Open Access Journal
issn 1177-889X
language English
last_indexed 2024-03-08T23:27:57Z
publishDate 2023-12-01
publisher Dove Medical Press
record_format Article
series Patient Preference and Adherence
spelling doaj.art-b4cfd91af1ca4e2c82449d1aa7337fb62023-12-14T17:01:45ZengDove Medical PressPatient Preference and Adherence1177-889X2023-12-01Volume 173265330388982What Do We Know about Medication Adherence Interventions in Inflammatory Bowel Disease, Multiple Sclerosis and Rheumatoid Arthritis? A Scoping Review of Randomised Controlled TrialsKing KMcGuinness SWatson NNorton CChalder TCzuber-Dochan WKathryn King,1 Serena McGuinness,1 Natalie Watson,1 Christine Norton,1 Trudie Chalder,2 Wladyslawa Czuber-Dochan1 1Florence Nightingale Faculty Nursing, Midwifery and Palliative Care, King’s College London, London, UK; 2Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UKCorrespondence: Kathryn King, Email Kathryn.king@kcl.ac.ukPurpose: Between 53% and 75% of people with inflammatory bowel disease, 30%– 80% with rheumatoid arthritis, and up to 50% with multiple sclerosis do not take medications as prescribed to maintain remission. This scoping review aimed to identify effective adherence interventions for inflammatory bowel disease, but with few studies found, multiple sclerosis and rheumatoid arthritis were included to learn lessons from other conditions.Methods: Full and pilot randomised controlled trials testing medication adherence interventions for inflammatory bowel disease, multiple sclerosis, and rheumatoid arthritis conducted between 2012 and 2021 were identified in six electronic databases.Results: A total of 3024 participants were included from 24 randomised controlled trials: 10 pilot and 14 full studies. Eight investigated inflammatory bowel disease, 12 rheumatoid arthritis, and four multiple sclerosis. Nine studies (37.5%) reported significantly improved medication adherence, all involving tailored, personalised education, advice or counselling by trained health professionals, with five delivered face-to-face and 1:1. Quality of effective interventions was mixed: five rated high quality, two medium and two low quality. Interventions predominantly using technology were likely to be most effective. Secondary tools, such as diaries, calendars and advice sheets, were also efficient in increasing adherence. Only 10 interventions were based on an adherence theory, of which four significantly improved adherence.Conclusion: Tailored, face-to-face, 1:1 interactions with healthcare professionals were successful at providing personalised adherence support. Accessible, user-friendly technology-based tools supported by calendars and reminders effectively enhanced adherence. Key components of effective interventions should be evaluated and integrated further into clinical practice if viable, whilst being tailored to inflammatory conditions.Plain Language Summary: Introduction: Inflammatory bowel disease (IBD), multiple sclerosis (MS), and rheumatoid arthritis (RA) are inflammatory diseases where the immune system causes inflammation by mistakenly attacking itself. These lifelong conditions cannot be cured, but can usually be controlled by medication. Medication is most effective when taken as prescribed, called “adherence”. For multiple reasons, between five and eight in 10 people with IBD, RA, and MS do not take medications as advised. This review aimed to identify research that tested ways to help people living with IBD, MS, and RA take medications as prescribed. Identifying and understanding what helps can increase patient well-being and improve quality of life through better controlled inflammatory conditions.Methods: Studies testing medication adherence interventions for IBD, MS, and RA conducted between 2012 and 2021 were identified from six electronic databases.Results: A total of 3024 people with inflammatory conditions took part in 24 studies (eight on IBD, four on MS, and 12 on RA). Nine studies reported significantly improved medication adherence, all involving personalised education, advice or counselling by trained health professionals, with five delivered face-to-face and individually. Interventions predominantly using technology were the most effective. Diaries, calendars, and advice sheets also increased adherence. Ten of the interventions were based on an adherence theory, of which four improved adherence.Conclusions: Personalised adherence support was successful when:tailored to patient,one-to-one and face-to-face,with healthcare professionals,involving technology-based tools, andsupported by calendars/reminders.Components of effective interventions should be used in clinical practice where possible, made specific to each inflammatory condition.Keywords: IBD, MS, RA, treatment, medicine, drug, concordancehttps://www.dovepress.com/what-do-we-know-about-medication-adherence-interventions-in-inflammato-peer-reviewed-fulltext-article-PPAibdmsratreatmentmedicinedrugconcordance.
spellingShingle King K
McGuinness S
Watson N
Norton C
Chalder T
Czuber-Dochan W
What Do We Know about Medication Adherence Interventions in Inflammatory Bowel Disease, Multiple Sclerosis and Rheumatoid Arthritis? A Scoping Review of Randomised Controlled Trials
Patient Preference and Adherence
ibd
ms
ra
treatment
medicine
drug
concordance.
title What Do We Know about Medication Adherence Interventions in Inflammatory Bowel Disease, Multiple Sclerosis and Rheumatoid Arthritis? A Scoping Review of Randomised Controlled Trials
title_full What Do We Know about Medication Adherence Interventions in Inflammatory Bowel Disease, Multiple Sclerosis and Rheumatoid Arthritis? A Scoping Review of Randomised Controlled Trials
title_fullStr What Do We Know about Medication Adherence Interventions in Inflammatory Bowel Disease, Multiple Sclerosis and Rheumatoid Arthritis? A Scoping Review of Randomised Controlled Trials
title_full_unstemmed What Do We Know about Medication Adherence Interventions in Inflammatory Bowel Disease, Multiple Sclerosis and Rheumatoid Arthritis? A Scoping Review of Randomised Controlled Trials
title_short What Do We Know about Medication Adherence Interventions in Inflammatory Bowel Disease, Multiple Sclerosis and Rheumatoid Arthritis? A Scoping Review of Randomised Controlled Trials
title_sort what do we know about medication adherence interventions in inflammatory bowel disease multiple sclerosis and rheumatoid arthritis a scoping review of randomised controlled trials
topic ibd
ms
ra
treatment
medicine
drug
concordance.
url https://www.dovepress.com/what-do-we-know-about-medication-adherence-interventions-in-inflammato-peer-reviewed-fulltext-article-PPA
work_keys_str_mv AT kingk whatdoweknowaboutmedicationadherenceinterventionsininflammatoryboweldiseasemultiplesclerosisandrheumatoidarthritisascopingreviewofrandomisedcontrolledtrials
AT mcguinnesss whatdoweknowaboutmedicationadherenceinterventionsininflammatoryboweldiseasemultiplesclerosisandrheumatoidarthritisascopingreviewofrandomisedcontrolledtrials
AT watsonn whatdoweknowaboutmedicationadherenceinterventionsininflammatoryboweldiseasemultiplesclerosisandrheumatoidarthritisascopingreviewofrandomisedcontrolledtrials
AT nortonc whatdoweknowaboutmedicationadherenceinterventionsininflammatoryboweldiseasemultiplesclerosisandrheumatoidarthritisascopingreviewofrandomisedcontrolledtrials
AT chaldert whatdoweknowaboutmedicationadherenceinterventionsininflammatoryboweldiseasemultiplesclerosisandrheumatoidarthritisascopingreviewofrandomisedcontrolledtrials
AT czuberdochanw whatdoweknowaboutmedicationadherenceinterventionsininflammatoryboweldiseasemultiplesclerosisandrheumatoidarthritisascopingreviewofrandomisedcontrolledtrials